A potential Dubin-Johnson syndrome imaging agent: Synthesis, biodistribution, and microPET imaging

Molecular Imaging

Volumn 4, Issue 1, 2005, Pages 18-29

  Yoo, Jeongsoo ^a   Reichert, David E ^a   Kim, Joonyoung ^a   Anderson, Carolyn J ^a   Welch, Michael J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biodistribution; Cu 64; DO3A derivatives; Dubin Johnson syndrome; MicroPET; Positron emission tomography

Indexed keywords

COMPLEXATION; COPPER; DATA REDUCTION; DERIVATIVES; DIAGNOSIS; POSITRON EMISSION TOMOGRAPHY; SYNTHESIS (CHEMICAL);

BIODISTRIBUTION; CU-64; DO3A DERIVATIVES; DUBIN-JOHNSON SYNDROME; MICROPET;

MEDICAL IMAGING;

1,4,7 TRIS(CARBOXYMETHYL) 1,4,7,10 TETRAAZACYCLODODECANE; 1,4,7-TRIS(CARBOXYMETHYL)-1,4,7,10-TETRAAZACYCLODODECANE; ACETIC ACID DERIVATIVE; CARRIER PROTEIN; COPPER; DIAGNOSTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; SINGLE HETEROCYCLIC RINGS;

ANIMAL; ARTICLE; BIOCHEMISTRY; FEMALE; GENETICS; HUMAN; ISOTOPE LABELING; JAUNDICE; METABOLISM; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; RAT; RAT STRAIN; SPRAGUE DAWLEY RAT; SYNTHESIS; TISSUE DISTRIBUTION;

ACETIC ACIDS; ANIMALS; BIOCHEMISTRY; COPPER RADIOISOTOPES; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; ISOTOPE LABELING; JAUNDICE, CHRONIC IDIOPATHIC; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, MUTANT STRAINS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 26944502783     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.1162/15353500200504160     Document Type: Article

References (47)

1. Dubin IN, Johnson FB (1954). Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. Medicine. 33:155-197.
2. Kajihara S, Hisatomi A, Mizuta T, Hara T, Ozaki I, Wada I, Yamamoto K (1998). A splice mutation in the human canalicular multispecific organic anions transporter gene causes Dubin-Johnson syndrome. Biochem Biophys Res Commun. 253:454-457.
3. Materna V, Lage H (2003). Homozygous mutation Arg768Trp in the ABC-transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin-Johnson syndrome in a Caucasian patient. J Hum Genet. 48:484-486.
4. Toh S, Wada M, Uchiumi T, Inokuchi A, Makino Y, Horie Y, Adachi Y, Sakisaka S, Kuwano M (1999). Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet. 64:739-746.
5. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, Tytgat GNJ, Borst P, Baas F, Oude Elferink RPJ (1997). A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology. 25:1539-1542.
6. Sekine T, Cha SH, Endou H (2000). The multispecific organic anion transporter (OAT) family. Pflugers Arch Eur J Physiol. 440:337-350.
7. Shimizu T, Tawa T, Maruyama T, Oguchi S, Yamashiro Y, Yabuta K (1997). A case of infantile Dubin-Johnson syndrome with high CT attenuation in the liver. Pediatr Radiol. 27:345-347.
8. Meholic AJ, Houston JD (2001). Hepatobiliary scintigraphy in an exacerbation of Dubin-Johnson syndrome. Clin Nucl Med. 26:643-644.
9. Pinos T, Constansa JM, Palacin A, Figueras C (1990). A new diagnostic approach to the Dubin-Johnson syndrome. Am J Gastroenterol. 85:91-93.
10. Bar-Meir S, Baron J, Seligson U, Gottesfeld F, Levy R, Gilat T (1982). 99mTc-HIDA cholescintigraphy in Dubin-Johnson and Rotor syndromes. Radiology. 142:743-746.
11. Jansen PL, Peters WH, Lamers WH (1985). Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology. 5:573-579.
12. Oude Elferink RP, Meijer DK, Kuipers F, Jansen PL, Groen AK, Groothuis GM (1995). Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim Biophys Acta. 1241:215-268.
13. Paulusma CC, Bosma PJ, Zaman GJR, Bakker CTM, Otter M, Scheffer GL, Scheper RJ, Borst P, Elferink RPJO (1996). Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science. 271:1126-1128.
14. Schwarz SW, Anderson CJ, Welch MJ (1994). Radiochemistry and radiopharmacology. In DR Bernier, PE Christian, and JK Langan (Eds.), Nuclear medicine technology and techniques (pp. 151-152). Mosby: St. Louis.
15. Wistow BW, Subramanian G, Heertum RL, Henderson RW, Gagne GM, Hall RC, McAfee JG (1977). An evaluation of 99mTc-labeled hepatobiliary agents. J Nucl Med. 18:455-461.
16. Jovanovic MS, Brboric J, Vladimirov S, Suturkova L (2000). Correlation between lipophilicity of the ligands and the hepato biliary properties of the radiopharmaceuticals: Approach to the development of new IDA derivatives. J Radioanal Nucl Chem. 245:555-560.
17. Anderson CJ, Welch MJ (1999). Radiometal-labeled agents (non-technetium) for diagnostic imaging, Chem Rev. 99:2219-2234.
18. 64Cu using a biomedical cyclotron. Nucl Med Biol. 24:35-43.
19. Lewis JS, Laforest R, Buettner TL, Song S-K, Fujibayashi Y, Connett JM, Welch MJ (2001). Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy. Proc Natl Acad Sci USA. 98:1206-1211.
20. Liu S, Edwards DS (2001). Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem. 12:7-34.
21. Glogard C, Hovland R, Fossheim SL, Aasen AJ, Klaveness J (2000). Synthesis and physicochemical characterisation of new amphiphilic gadolinium DO3A complexes as contrast agents for MRI. J Chem Soc, Perkin Trans. 2:1047-1052.
22. Baker WC, Choi MJ, Hill DC, Thompson JL, Petillo PA (1999). Synthesis of lipophilic paramagnetic contrast agents. J Org Chem. 64:2683-2689.
23. Yoo J, Reichert DE, Welch MJ (2003). Regioselective N-substitution of cyclen with two different alkyl groups: Synthesis of all possible isomers. Chem Commun. 766-767.
24. Mathias CJ, Bergmann SR, Green MA (1995). Species-dependent binding of copper(II) bis(thiosemicarbazone) radiopharmaceuticals to serum albumin. J Nucl Med. 36:1451-1455.
25. Cherry SR, Shao Y, Silverman RW, Meadors K, Siegel S, Chatziioannou A, Young JW, Jones WF, Moyers JC, Newport D, Boutefnouchet A, Farquhar TH, Andreaco M, Paulus MJ, Binkley DM, Nutt R, Phelps ME (1997). MicroPET: A high resolution PET scanner for imaging small animals. IEEE Trans Nucl Sci. 44:1161-1166.
26. Li WP, Lewis JS, Kim J, Bugaj JE, Johnson MA, Erion JL, Anderson CJ (2002). DOTA-D-Tyrl-Octreotate: A somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. Bioconjug Chem. 13:721-728.
27. Wipke BT, Wang Z, Kim J, McCarthy TJ, Allen PM (2002). Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat Immunol. 3:366-372.
28. Oyama N, Kim J, Jones LA, Mercer NM, Engelbach JA, Sharp TL, Welch MJ (2002). MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl Med Biol. 29:783-790.
29. Oyama N, Ponde DE, Dence C, Kim J, Tai Y-C, Welch MJ (2004). Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation, J Nucl Med. 45:519-525.
30. Thrall JH, Ziessman HA (2001). Hepatobiliary system. In Nuclear medicine the requisites (pp. 228-264). Mosby: St. Louis.
31. Dadabhoy A, Faulkner S, Sammes PG (2002). Long wavelength sensitizers for europium(III) luminescence based on acridone derivatives. J Chem Soc, Perkin Trans. 2:348-357.
32. Mukai T, Namba S, Arano Y, Ono M, Fujioka Y, Uehara T, Ogawa K, Konishi J, Saji H (2002). Synthesis and evaluation of a monoreactive DOTA derivative for indium-111-based residualizing label to estimate protein pharmacokinetics. J Pharm Pharmacol. 54:1073-1081.
33. Yoo J, Reichert DE, Welch MJ (2004). Comparative in vivo behavior studies of cyclen-based copper-64 complexes: Regioselective synthesis, X-ray structure, radiochemistry, log P, and biodistribution. J Med Chem. 47:6625-6637.
34. Meyer M, Dahaoui-Gindrey V, Lecomte C, Guilard R (1998). Conformations and coordination schemes of carboxylate and carbamoyl derivatives of the tetraazamacrocycles cyclen and cyclam, and the relation to their protonation states. Coord Chem Rev. 178-180:1313-1405.
35. Zmbova B, Djokic D, Ninkovic D, Obradovic V, Kostic K (1987). Chemical and biological properties of 2,6-diisopropyl IDA labeled with technetium-99m. Appl Radiat Isot. 38:35-40.
36. Krishnamurthy S, Krishnamurthy GT (1989). Technetium-99m-iminodiacetic acid organic anions: Review of biokinetics and clinical application in hepatology. Hepatology. 9:139-153.
37. Rehling M, Nielsen LE, Marqversen J (2001). Protein binding of 99Tcm-DTPA compared with other GFR tracers. Nucl Med Commun. 22:617-623.
38. Jeghers O, Piepsz A, Ham HR (1990). What does protein binding of radiopharmaceuticals mean exactly? Eur J Nucl Med. 17:101-102.
39. Nunn AD, Loberg MD, Conley RA (1983). A structure-distribution- relationship approach leading to the development of technetium-99m-labeled mebrofenin: An improved cholescintigraphic agent. J Nucl Med 24:423-430.
40. Packard AB, Srivastava SC, Richards P, Meinken GE, Ford L, Benson WR (1989). Synthesis and biological properties of the lipophilic technetium-99m complex 99mTc(acac)3. Nucl Med Biol. 16:291-294.
41. Chauhan UP, Chander J, Mishra P (1990). 99mTc-labelled trimethylmonoiodo-IDA: A new radiopharmaceutical for hepatobiliary imaging. Int J Rad Appl Instrum B. 17:401-408.
42. Martini FH (2004). The urinary system. In Fundamentals of anatomy and physiology (pp. 970-1013). San Francisco: Benjamin Cummings.
43. - rats with a hepatobiliary secretion defect. Am J Pbysiol. 265:G445-G452.
44. Cutler PD, Schwarz SW, Anderson CJ, Connett JM, Welch MJ, Philpott GW, Siegel BA (1995). Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso. J Nucl Med. 36:2363-2371.
45. Philpott GW, Schwarz SW, Anderson CJ, Dehdashti F, Connett JM, Zinn KR, Meares CF, Cutler PD, Welch MJ, Siegel BA (1995). RadioimmunoPET: Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med. 36:1818-1824.
46. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 42:213-221.
47. Blower PJ, Lewis JS, Zweit J (1996). Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol. 23:957-980.